Canaccord raised the firm’s price target on AtriCure (ATRC) to $53 from $49 and keeps a Buy rating on the shares. The firm said they beat Q3 estimates and management raised Q4 guidance. The solid quarter was driven broadly across the businesses, aside from minimally invasive ablation/EPi-Sense, which continues to face expected headwinds from PFA adoption. Management remains steadfast that these headwinds will subside, pointing towards its experience in Europe.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC: